AU2007356942B2 - Pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof - Google Patents

Pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof Download PDF

Info

Publication number
AU2007356942B2
AU2007356942B2 AU2007356942A AU2007356942A AU2007356942B2 AU 2007356942 B2 AU2007356942 B2 AU 2007356942B2 AU 2007356942 A AU2007356942 A AU 2007356942A AU 2007356942 A AU2007356942 A AU 2007356942A AU 2007356942 B2 AU2007356942 B2 AU 2007356942B2
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
lercanidipine
calcium channel
composition according
channel antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2007356942A
Other languages
English (en)
Other versions
AU2007356942A1 (en
Inventor
Evangelos Karavas
Ioanna Koutri
Efthimios Koutris
Eleni Stathaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmathen SA
Original Assignee
Pharmathen SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39223083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2007356942(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmathen SA filed Critical Pharmathen SA
Publication of AU2007356942A1 publication Critical patent/AU2007356942A1/en
Application granted granted Critical
Publication of AU2007356942B2 publication Critical patent/AU2007356942B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
AU2007356942A 2007-07-23 2007-07-23 Pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof Active AU2007356942B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2007/006517 WO2009012791A1 (en) 2007-07-23 2007-07-23 Pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof

Publications (2)

Publication Number Publication Date
AU2007356942A1 AU2007356942A1 (en) 2009-01-29
AU2007356942B2 true AU2007356942B2 (en) 2011-12-15

Family

ID=39223083

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2007356942A Active AU2007356942B2 (en) 2007-07-23 2007-07-23 Pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof
AU2008280106A Ceased AU2008280106B9 (en) 2007-07-23 2008-07-23 Improved pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2008280106A Ceased AU2008280106B9 (en) 2007-07-23 2008-07-23 Improved pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof

Country Status (20)

Country Link
EP (2) EP2180883B1 (enExample)
JP (2) JP5769963B2 (enExample)
KR (2) KR101632079B1 (enExample)
CN (3) CN101784260A (enExample)
AU (2) AU2007356942B2 (enExample)
BR (2) BRPI0721883A2 (enExample)
CA (2) CA2691752C (enExample)
CO (1) CO6290639A2 (enExample)
CR (1) CR11285A (enExample)
EA (2) EA021645B1 (enExample)
EC (1) ECSP109984A (enExample)
ES (2) ES2622495T3 (enExample)
MA (1) MA31684B1 (enExample)
MX (2) MX2010000856A (enExample)
MY (1) MY153857A (enExample)
NZ (2) NZ582648A (enExample)
TN (2) TN2010000011A1 (enExample)
UA (2) UA97161C2 (enExample)
WO (2) WO2009012791A1 (enExample)
ZA (2) ZA201000586B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
KR101632079B1 (ko) * 2007-07-23 2016-06-20 파마덴 에스.에이. 디히드로피리딘 칼슘 채널 길항제를 함유하는 약제학적 조성물 및 그것의 제조방법
CA2738573C (en) 2009-04-03 2013-02-19 F. Hoffmann-La Roche Ag Compositions of propane-1 sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide and uses thereof
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
JP2013510166A (ja) 2009-11-06 2013-03-21 プレキシコン インコーポレーテッド キナーゼ調節のための化合物、方法およびその適用
PE20141360A1 (es) 2011-02-07 2014-10-13 Plexxikon Inc Compuestos y metodos para la modulacion de quinasas e indicaciones para los mismos.
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
US10835495B2 (en) 2012-11-14 2020-11-17 W. R. Grace & Co.-Conn. Compositions containing a biologically active material and a non-ordered inorganic oxide material and methods of making and using the same
GR1008554B (el) * 2014-06-12 2015-09-03 ΦΑΡΜΑΤΕΝ ΑΝΩΝΥΜΟΣ ΒΙΟΜΗΧΑΝΙΚΗ ΚΑΙ ΕΜΠΟΡΙΚΗ ΕΤΑΙΡΕΙΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΙΑΤΡΙΚΩΝ ΚΑΙ ΚΑΛΛΥΝΤΙΚΩΝ ΠΡΟΪΟΝΤΩΝ με δ.τ. ΦΑΡΜΑΤΕΝ, Φαρμακευτικο σκευασμα περιεχον εναν αντιμυκητιασικο παραγοντα τριaζολης και μεθοδος για την παρασκευη αυτου
CN104069500A (zh) * 2014-06-20 2014-10-01 湖南天地恒一制药有限公司 一种包含乐卡地平的药物组合物
CN105168165B (zh) * 2015-08-28 2018-06-26 江苏福邦药业有限公司 一种盐酸乐卡地平片及其制备方法
WO2018004379A1 (ru) * 2016-07-01 2018-01-04 Общество С Ограниченной Ответственностью "Гиостин" Средство в виде капсулы для лечения заболеваний суставов
WO2019165420A1 (en) 2018-02-26 2019-08-29 R.P. Scherer Technologies, Llc Pharmaceutical dosage form for an emulsion of simethicone and loperamide
CA3094115A1 (en) 2018-03-22 2019-09-26 Komipharm International Australia Pty Ltd Pharmaceutical composition comprising meta arsenite and method of manufacture
JP2023107429A (ja) * 2022-01-24 2023-08-03 東芝テック株式会社 読取装置
CN114533686B (zh) * 2022-02-15 2023-10-20 湖南普道医药技术有限公司 一种二氢吡啶类药物的口服固体制剂及其制备方法
KR20240040407A (ko) * 2022-09-21 2024-03-28 주식회사 종근당 사쿠비트릴ㆍ발사르탄 칼슘염을 포함하는 약제학적 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0487335A1 (en) * 1990-11-20 1992-05-27 Montague Cecil Solomon Pharmaceutical dosage forms of dihydropyridines
EP1013271A2 (en) * 1998-12-15 2000-06-28 Oscar Gold Nimodipine tablets
WO2004066910A2 (en) * 2003-01-31 2004-08-12 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
WO2005053689A2 (en) * 2003-12-01 2005-06-16 Lifecycle Pharma A/S Pharmaceutical compositions comprising lercanidipine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3720757A1 (de) * 1987-06-24 1989-01-05 Bayer Ag Dhp-manteltablette
US5209933A (en) * 1990-01-10 1993-05-11 Syntex (U.S.A.) Inc. Long acting calcium channel blocker composition
DE19944803A1 (de) * 1999-09-20 2001-03-29 Bayer Ag Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
UA89177C2 (ru) * 2003-12-01 2010-01-11 Рекордати Айрленд Лимитед Фармацевтическая композиция с контролируемым высвобождением, которая содержит лерканидипин
EP2063872B2 (en) * 2006-08-30 2019-12-04 Jagotec AG Controlled release oral dosage formulations comprising a core and one or more barrier layers
WO2008068777A2 (en) * 2006-12-06 2008-06-12 Torrent Pharmaceuticals Limited Stable lercanidipine formulation
KR101632079B1 (ko) * 2007-07-23 2016-06-20 파마덴 에스.에이. 디히드로피리딘 칼슘 채널 길항제를 함유하는 약제학적 조성물 및 그것의 제조방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0487335A1 (en) * 1990-11-20 1992-05-27 Montague Cecil Solomon Pharmaceutical dosage forms of dihydropyridines
EP1013271A2 (en) * 1998-12-15 2000-06-28 Oscar Gold Nimodipine tablets
WO2004066910A2 (en) * 2003-01-31 2004-08-12 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
WO2005053689A2 (en) * 2003-12-01 2005-06-16 Lifecycle Pharma A/S Pharmaceutical compositions comprising lercanidipine

Also Published As

Publication number Publication date
EP2170295A1 (en) 2010-04-07
ZA201000586B (en) 2011-03-30
NZ582690A (en) 2011-12-22
EP2180883B1 (en) 2017-01-11
BRPI0721883A2 (pt) 2014-02-18
CN103976968A (zh) 2014-08-13
AU2008280106A1 (en) 2009-01-29
NZ582648A (en) 2012-06-29
JP5769963B2 (ja) 2015-08-26
CA2691752C (en) 2016-01-26
CR11285A (es) 2010-04-27
KR20100047848A (ko) 2010-05-10
CA2691752A1 (en) 2009-01-29
ES2537063T3 (es) 2015-06-02
MX2010000856A (es) 2010-04-30
ZA201001176B (en) 2010-11-24
UA97161C2 (ru) 2012-01-10
MA31684B1 (fr) 2010-09-01
ECSP109984A (es) 2010-04-30
AU2008280106B2 (en) 2014-03-20
WO2009012791A1 (en) 2009-01-29
TN2010000022A1 (en) 2011-09-26
AU2008280106A2 (en) 2010-02-25
TN2010000011A1 (en) 2011-09-26
EP2170295B1 (en) 2015-04-22
CN101784260A (zh) 2010-07-21
CO6290639A2 (es) 2011-06-20
AU2007356942A1 (en) 2009-01-29
EA201070160A1 (ru) 2010-06-30
CN101801347A (zh) 2010-08-11
KR20100045456A (ko) 2010-05-03
MY153857A (en) 2015-03-31
CA2693233A1 (en) 2009-01-29
EP2180883A1 (en) 2010-05-05
EA019614B1 (ru) 2014-05-30
EA021645B1 (ru) 2015-08-31
KR101512404B1 (ko) 2015-04-21
WO2009013306A1 (en) 2009-01-29
EA201000220A1 (ru) 2010-08-30
KR101632079B1 (ko) 2016-06-20
ES2622495T3 (es) 2017-07-06
BRPI0814666A2 (pt) 2017-05-09
JP2010534211A (ja) 2010-11-04
JP2010534220A (ja) 2010-11-04
UA99136C2 (ru) 2012-07-25
MX2010000801A (es) 2010-07-05
AU2008280106B9 (en) 2014-08-07

Similar Documents

Publication Publication Date Title
CA2691752C (en) Pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof
US12138255B2 (en) Pharmaceutical compositions of cabozantinib
JPWO2018199282A1 (ja) エンザルタミドを含有する経口投与用医薬組成物
CA2696977C (en) Improved pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof
AU2003240164A1 (en) Extended release formulation of divalproex sodium
EP2197424A2 (en) Improved pharmaceutical composition containing antiviral agent and method for the preparation thereof
US20110257159A1 (en) Orally disintegrating tablet formulations of mirtazapine and process for preparing the same
US20080221079A1 (en) Pharmaceutical composition of quetiapine fumarate
EP2303233B1 (en) Solid oral dosage form containing anti-platelet agent clopidogrel and method for the preparation thereof
HK1199221A1 (en) Pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof
HK1141726A (en) Pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)